32,837 Shares in CVS Health Corporation $CVS Acquired by Axecap Investments LLC

Axecap Investments LLC acquired a new position in shares of CVS Health Corporation (NYSE:CVS) during the third quarter, Holdings Channel.com reports. The institutional investor acquired 32,837 shares of the pharmacy operator’s stock, valued at approximately $2,814,000. CVS Health makes up about 1.7% of Axecap Investments LLC’s investment portfolio, making the stock its 21st biggest position.

Several other large investors also recently added to or reduced their stakes in CVS. Carnegie Investment Counsel raised its holdings in shares of CVS Health by 3.6% during the 3rd quarter. Carnegie Investment Counsel now owns 39,461 shares of the pharmacy operator’s stock worth $3,381,000 after acquiring an additional 1,357 shares during the period. Robeco Institutional Asset Management B.V. grew its holdings in shares of CVS Health by 4.1% in the third quarter. Robeco Institutional Asset Management B.V. now owns 2,091,736 shares of the pharmacy operator’s stock valued at $179,241,000 after purchasing an additional 82,976 shares during the period. 55 North Private Wealth LLC grew its holdings in shares of CVS Health by 16.3% in the third quarter. 55 North Private Wealth LLC now owns 5,120 shares of the pharmacy operator’s stock valued at $439,000 after purchasing an additional 719 shares during the period. Flagship Capital Management Inc. increased its position in CVS Health by 1.1% during the third quarter. Flagship Capital Management Inc. now owns 29,198 shares of the pharmacy operator’s stock worth $2,502,000 after purchasing an additional 319 shares during the last quarter. Finally, Sumitomo Mitsui DS Asset Management Company Ltd increased its position in CVS Health by 0.7% during the third quarter. Sumitomo Mitsui DS Asset Management Company Ltd now owns 191,455 shares of the pharmacy operator’s stock worth $16,406,000 after purchasing an additional 1,395 shares during the last quarter. 80.66% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

Several research firms have weighed in on CVS. UBS Group reiterated a “buy” rating on shares of CVS Health in a report on Tuesday, September 22nd. JPMorgan Chase & Co. raised their price target on shares of CVS Health from $111.00 to $118.00 and gave the stock an “overweight” rating in a report on Wednesday, August 12th. Piper Sandler set a $112.00 price target on shares of CVS Health in a research report on Wednesday, September 9th. Truist Financial upped their price objective on CVS Health from $108.00 to $118.00 and gave the company a “buy” rating in a report on Tuesday, July 14th. Finally, Wall Street Zen lowered CVS Health from a “strong-buy” rating to a “buy” rating in a research report on Monday. Twenty research analysts have rated the stock with a Buy rating and three have given a Hold rating to the company’s stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $107.80.

CVS Health Stock Up 2.3%

Shares of NYSE CVS opened at $94.77 on Wednesday. The firm has a market cap of $121.21 billion, a price-to-earnings ratio of 25.07, a PEG ratio of 0.86 and a beta of 0.60. The company has a quick ratio of 0.66, a current ratio of 0.87 and a debt-to-equity ratio of 0.74. CVS Health Corporation has a 52-week low of $69.51 and a 52-week high of $110.68. The business’s 50 day moving average is $91.70 and its two-hundred day moving average is $93.49.

CVS Health (NYSE:CVS) last released its quarterly earnings results on Wednesday, August 5th. The pharmacy operator reported $2.58 EPS for the quarter, topping analysts’ consensus estimates of $1.87 by $0.71. CVS Health had a return on equity of 13.12% and a net margin of 1.18%. The company had revenue of $106.10 billion for the quarter, compared to analysts’ expectations of $100.03 billion. During the same period in the prior year, the firm earned $1.81 earnings per share. The firm’s revenue was up 7.3% compared to the same quarter last year. CVS Health has set its FY 2026 guidance at 7.900-8.100 EPS. Research analysts predict that CVS Health Corporation will post 8.02 EPS for the current year.

CVS Health Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Monday, November 2nd. Investors of record on Thursday, October 22nd will be paid a dividend of $0.6650 per share. The ex-dividend date of this dividend is Thursday, October 22nd. This represents a $2.66 annualized dividend and a yield of 2.8%. CVS Health’s dividend payout ratio is presently 70.37%.

CVS Health News Summary

Here are the key news stories impacting CVS Health this week:

• Positive Sentiment: Opportunity to gain pharmacy customers: CVS is targeting customers displaced by Walgreens and Rite Aid store closures. The initiative could support prescription volume, retail sales and customer retention if CVS successfully converts those patients. CVS targets former Walgreens, Rite Aid customers after 1,000 stores close
• Positive Sentiment: Aetna administrative improvements: CVS says Aetna is streamlining prior authorizations, approving more than 95% of eligible requests within 24 hours and expanding bundled approvals. Faster decisions could improve member and provider satisfaction while reducing administrative costs. How CVS’ Aetna Is Advancing Efforts to Reduce Administrative Burden
• Positive Sentiment: MinuteClinic expansion: Three new Massachusetts locations—including the first in Boston—expand CVS’s healthcare footprint and may increase patient traffic, service revenue and cross-selling opportunities. MinuteClinic opens three new retail medical clinics
• Neutral Sentiment: Leadership transition: Chief Information Officer Amaresh Siva is leaving CVS to become Alaska Airlines’ chief information technology officer. The departure may create near-term technology and AI execution uncertainty, though it does not directly change CVS’s financial outlook. Alaska Airlines taps CVS Health executive for new technology role
• Negative Sentiment: Industry and valuation concerns: Coverage highlights pressure from rising medical costs across managed care, uncertainty surrounding Medicare Advantage plan availability and technical weakness after CVS raised its outlook. These issues could limit valuation expansion despite the company’s improved earnings guidance. Management raised the bar for CVS Health stock

About CVS Health

CVS Health Corporation (NYSE: CVS) is a diversified health care company that provides pharmacy, insurance and health services in the United States. Its businesses serve consumers, employers, health plans and health care providers through pharmacies, benefit programs, insurance coverage and clinical care services.

The company’s Pharmacy Services segment, led by CVS Caremark, manages prescription drug benefits for employers, insurers and government programs. CVS Pharmacy operates retail pharmacies and health-focused stores that dispense prescriptions and offer over-the-counter products, health and wellness merchandise, immunizations and related services.